JoBen

JoBen Bioscience is a clinical-stage biotechnology company based in Shanghai, China, focused on the discovery and development of innovative targeted protein degradation (TPD) therapies. Utilizing its proprietary PROTAC platform, the company develops small molecule degraders designed to eliminate pathogenic proteins that are often inaccessible to traditional small molecule inhibitors. JoBen's lead programs target the androgen receptor for prostate cancer and other key drivers in oncology and immunology. The company aims to address drug resistance and improve clinical outcomes for patients with solid tumors and hematological malignancies. By leveraging deep expertise in medicinal chemistry and protein biology, JoBen is advancing a robust pipeline of next-generation degraders through clinical development.